Increased expression of estrogen receptor α-36 by breast cancer oncogene IKKε promotes growth of ER-negative breast cancer cells

Cellular Physiology and Biochemistry

Volumn 31, Issue 6, 2013, Pages 833-841

  Li, Qihong ^a,b,c   Sun, Haiyan ^c   Zou, Jingcai ^c   Ge, Cheng ^c   Yu, Kaitao ^c   Cao, Yuan ^d   Hong, Quan ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^d JINAN MILITARY GENERAL HOSPITAL   (China)

Author keywords

ER negative breast cancer; ER 36; IKK

Indexed keywords

ERBIUM; ESTROGEN RECEPTOR ALPHA; I 4907; I KAPPA B KINASE EPSILON; UNCLASSIFIED DRUG; ESTROGEN; ESTROGEN RECEPTOR ALPHA 36; SERINE;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CONTROLLED STUDY; HUMAN; HUMAN CELL; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; UPREGULATION; WESTERN BLOTTING; CANCER PROGNOSIS; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN TISSUE; IKK EPSILON GENE; PROTEIN DNA BINDING; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSACTIVATION;

EID: 84879469644     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000350101     Document Type: Article

References (23)

1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31, 31. (Pubitemid 29094959)
2. Osborne CK, Schiff R: Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 2011;62:233-247.
3. Speirs V, Skliris G P, Burdall SE, Carder PJ: Distinct expression patterns of er alpha and er beta in normal human mammary gland. J Clin Pathol 2002;55:371-374. (Pubitemid 34494177)
4. Giuliano M, Schifp R, Osborne CK, Trivedi MV: Biological mechanisms and clinical implications of endocrine resistance in breast cancer. Breast 2011;20:S42-49.
5. Wang D, Huang P, Zhu B, Sun L, Huang Q, Wang J: Induction of estrogen receptor alpha-36 expression by bone morphogenetic protein 2 in breast cancer cell lines. Mol Med Rep 2012;6:591-596.
6. Fowler AM, Santen RJ, Allred DC: "Dwarf" estrogen receptor in breast cancer and resistance to tamoxifen. J Clin Oncol 2009;27:3413-3415.
7. Masood S: Estrogen and progesterone receptors in cytology: A comprehensive review. Diagn Cytopathol 1992;8:475-491.
8. McGuire WL, Chamness GC, Fuqua SA: Estrogen receptor variants in clinical breast cancer. Mol Endocrinol 1991;5:1571-1577.
9. Johnston SR: New strategies in estrogen receptor-positive breast cancer. Clin Cancer Res 2010;16:1979-1987.
10. Chen JQ, Russo J: Eralpha-negative and triple negative breast cancer: Molecular features and potential therapeutic approaches. Biochim Biophys Acta 2009;1796:162-175.
11. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, Deuel TF: A variant of estrogen receptor-α, her-α36: Transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Nat Acad Sci USA 2006;103:9063-9068. (Pubitemid 43902533)
12. Zhang X, Ding L, Kang L, Wang ZY: Estrogen receptor-alpha 36 mediates mitogenic antiestrogen signaling in ernegative breast cancer cells. PloS One 2012;7:e30174.
13. Shi L, Dong B, Li Z, Lu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Wang Z, Xie Y: Expression of er-α36, a novel variant of estrogen receptor α, and resistance to tamoxifen treatment in breast cancer. J Clin Oncol 2009;27:3423-3429.
14. Zhang XT, Kang LG, Ding L, Vranic S, Gatalica Z, Wang ZY: A positive feedback loop of er-alpha36/egfr promotes malignant growth of er-negative breast cancer cells. Oncogene 2011;30:770-780.
15. Clement JF, Meloche S, Servant MJ: The ikk-related kinases: From innate immunity to oncogenesis. Cell Res 2008;18:889-899.
16. Hacker H, Karin M: Regulation and function of ikk and ikk-related kinases. Sci STKE 2006;2006:re13.
17. Shen RR, Hahn WC: Emerging roles for the non-canonical ikks in cancer. Oncogene 2011;30:631-641.
18. Tenoever BR, Ng SL, Chua MA, McWhirter SM, Garcia-Sastre A, Maniatis T: Multiple functions of the ikk-related kinase ikkepsilon in interferon-mediated antiviral immunity. Science 2007;315:1274-1278. (Pubitemid 46364264)
19. Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, Sjostrom SK, Garraway LA, Weremowicz S, Richardson AL, Greulich H, Stewart CJ, Mulvey LA, Shen RR, Ambrogio L, Hirozane-Kishikawa T, Hill DE, Vidal M, Meyerson M, Grenier JK, Hinkle G, Root DE, Roberts TM, Lander ES, Polyak K, Hahn WC: Integrative genomic approaches identify ikbke as a breast cancer oncogene. Cell 2007;129:1065-1079. (Pubitemid 46891036)
20. Guo JP, Shu SK, Esposito NN, Coppola D, Koomen JM, Cheng JQ: Ikkepsilon phosphorylation of estrogen receptor alpha ser-167 and contribution to tamoxifen resistance in breast cancer. J Biol Chem 2010;285:3676-3684.
21. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108. (Pubitemid 40372904)
22. Yamashita H, Yando Y, Nishio M, Zhang Z, Hamaguchi M, Mita K, Kobayashi S, Fujii Y, Iwase H: Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer. Breast Cancer 2006;13:74-83.
23. Hutti JE, Shen RR, Abbott DW, Zhou AY, Sprott KM, Asara JM, Hahn WC, Cantley LC: Phosphorylation of the tumor suppressor cyld by the breast cancer oncogene ikkepsilon promotes cell transformation. Mol Cell 2009;34:461-472.